This study is looking at new ways to help young people (ages 15-24) with mild depression. Researchers are testing N-acetylcysteine (NAC), a drug, and Mindfulness-based cognitive therapy (MBCT), a type of talk therapy, either alone or in combination. They are also comparing these to a placebo (an inactive pill) and a sham (fake) mindfulness intervention. The main goal is to see if these treatments change levels of glutamate (a brain chemical) in a specific part of the brain called the left ventrolateral prefrontal cortex (VLPFC). This could help us understand how these treatments work to improve depression. The study is currently recruiting 160 participants.

Study design

This is an interventional study planning to enroll 160 participants. It compares N-acetylcysteine, Mindfulness-based cognitive therapy, placebo, and a sham mindfulness intervention.

What's involved

The primary endpoint, measuring glutamate levels, is taken from baseline to week 8. Specific details about visits or procedures are not specified.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured from baseline to week 8.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.